Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)

Korábbi kezelés

• Concomitant clinically significant other liver diseases;
• Previous/current manifestations of hepatic decompensation;
• Participants with recent major trauma or major surgery, or planning surgery;
• Those who are participating in another clinical trial, or have not undergone a protocol-specified washout period prior to this study;
• Prior/current use of prohibited medications;

Más betegség

• Clinically significant abnormalities other than a history of chronic HBV infection;
• History of malignancy or ongoing assessment of possible malignancy;
• Those allergic to AHB-137 or its components;

Laborértékek

• Presence of protocol-specified laboratory abnormalities;

Egyéb

• Significant hepatic fibrosis or cirrhosis;
• Inappropriate for participation in this trial as judged by the investigator.

• Participants voluntarily participate in the study, and sign the Informed Consent Form (ICF) prior to screening, able to complete the study according to the protocol;
• At least 18 years of age at the time of signing the ICF;
• Body mass index met the requirements;
• HBeAg negative at screening;
• HBsAg or HBV DNA positive for at least 6 months;
• Meet relevant requirements for NAs treatment;
• 100 IU/mL < HBsAg ≤ 3000 IU/mL, HBV DNA < 100 IU/mL and liver function indicators meet the requirements;
• Effective contraception as required.